On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Is Avadel Pharmaceuticals Stock A Buy?
Avadel Pharmaceuticals stock is building a cup with handle with a 17.16 entry. See if the biotech stock can clear the breakout price in heavy trading.
The biotech firm showed 0% earnings growth in the latest quarterly report. Sales rose -100%. Keep an eye out for the company's next round of numbers on or around Aug. 8.
Avadel Pharmaceuticals stock earns the No. 136 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Alnylam Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
